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Blood culture methods show low sensitivity, so reliable non−culture diagnostic tests are needed to help
clinicians with the introduction, de-escalation, and discontinuation of antifungal therapy in patients with
suspected invasive candidiasis (IC). We evaluated different biomarkers for the diagnosis of IC in immuno-
competent and immunocompromised patients at risk for developing invasive fungal diseases. The specificity
of Candida albicans germ-tube antibodies (CAGTA) detection was high (89%100%), but sensitivity did not
exceed 61% even after raising the cut-off from 1/160 to 1/80. We developed enzyme-linked immunoassays
detecting antibodies against C. albicans proteins (Als3-N, Hwp1-N, or Met6) that resulted more sensitive
(66%92%) but less specific than CAGTA assay. The combination of 1,3-beta-D-glucan (BDG) detection and
CAGTA results provided the highest diagnostic usefulness in immunocompetent patients. However, in
immunocompromised patients, anti−Met6 antibodies was the best biomarker, both, alone or in combination
with BDG.
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Invasive candidiasis (IC) is a leading cause of mycosis-associated
mortality in hospitals of developed countries with a high attributable
mortality 40% to 50% despite treatment with antifungal agents
(Edmond et al., 1999, Gudlaugsson et al., 2003). Population-based
studies have reported incidence rates of 1.4 to 20 per 100,000 inhabi-
tants (Quindos, 2014).
The incidence of IC in immunocompromised patients has
increased as a consequence of factors such as long-term hospitaliza-
tion, acquired immunodeficiency (HIV infection), treatment-induced
immunodeficiency in patients receiving hematopoietic stem-cell or
solid organ transplants, as well as those undergoing anticancer ther-
apy (Kontoyiannis et al., 2010, Pagano et al., 2010, Pappas et al.,
2010). These patients can not eliminate efficiently this opportunisticand commensal fungus (Brown et al., 2012). Furthermore, IC also
extends the length of hospital stay and increases the cost of medical
care (Quindos, 2014, Diekema et al., 2012).
The diagnosis of IC is challenging because there are no specific
clinical manifestations, and colonization and infection are difficult to
distinguish. Conventional microbiological methods, such as the
detection of the infecting fungus by histopathology and culture, usu-
ally lack both sensitivity, and specificity (Morrell et al., 2005). Blood
culture remains the “gold standard,” delaying the possible therapeu-
tic intervention and resulting in substantial morbidity and mortality
(Lew, 1989). Because of these shortcomings, there is a great interest
in developing reliable non−culture diagnostic tests, but none has
found widespread clinical use yet.
A 12 to 24 hours delay in the introduction of the antifungal
treatment can double the mortality of candidemia (Morrell et al.,
2005), so new early detection tests are needed to anticipate the
specific antifungal treatment. Moreover, appropriate diagnostic
techniques to exclude IC in patients at high risk, would allow de-
escalation or discontinuation of antifungal agents, reducing
healthcare costs, and the risk of inducing possible resistance to
these drugs.
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detect Candida albicans germ tube antibodies (CAGTA) in patients at
risk of IC that allows distinguishing colonization from invasion (Gar-
cía-Ruiz et al., 1997, Moragues et al., 2004). Saez-Roson et al. (2014,
2015) identified agglutinin-like-sequence (Als3), hyphal-wall protein
(Hwp1) and methionine synthase (Met6) among the main proteins
recognized by CAGTA developed in a rabbit model of IC. Therefore,
we aimed at evaluating the detection of specific antibodies against
Als3, Hwp1, and Met6 by an enzyme linked immunosorbent assay
(ELISA), as useful markers for the diagnosis of IC in immunocompe-
tent, and immunocompromised patients with risk factors for devel-
oping an invasive fungal disease (IFD). Data were compared with the
results of (Ardizzoni et al., 2014, Brown et al., 2012, Clancy et al.,
2008) 1,3-b-D-glucan (BDG) determination and CAGTA assay to
assess the diagnostic utility of these serum biomarkers.
2. Patients and methods
2.1. Patients and methods
We studied 627 sera from 297 patients. Sera were collected pro-
spectively at the Severo Ochoa University Hospital (Leganes-Madrid)
and Cruces University Hospital (Barakaldo-Bizkaia), and stored at
-20°C. Patients were classified into 3 groups according to clinical, and
microbiological data. Group 1 included 126 patients (332 sera) with
IC proven by a positive blood culture. Group 2 gathered 66 patients
(164 sera) with other fungal infections, mainly Aspergillus, and Pneu-
mocystis infections. Group 3 included 105 patients (131 sera) with no
evidence of IFD. Patients were further classified as immunocompe-
tent or immunocompromised. The sera collection is anonymized and
registered (C.0005025) at the Instituto de Salud Carlos III, Spain.
2.2. Serum antibodies against germ tubes of C. albicans
The CAGTA titer was calculated as reported by Moragues et al.
(2004) with some modifications. Briefly, 20 mL of 1/4 diluted serum
in phosphate-buffered saline (PBS; 10 mM Na2HPO4, 1.8 mM KH2PO4,
137 mM NaCl, pH 7.2) was added to 80 mL of sorbent (heat-inacti-
vated C. albicans blastospores 1010/mL of PBS) to achieve a final 1/20
dilution of the sample. Twenty mL of 1/20 diluted serum and serial
half dilutions in PBS were laid in each well of a slide containing fixed
germinated C. albicans cells, and left to incubate for 30 minutes at 37°
C in a humid chamber. The slides were washed with PBS for 5
minutes with gentle agitation, and left to dry in the air. Then, 10 mL
of FITC-conjugated antihuman-IgG antibodies diluted 1/150 in PBS
containing 0.05% Tween 20 and 0.05% Evans Blue was added and
incubated once more for 30 minutes in the same conditions. The
slides were washed again and left to dry. Coverslips were laid down
with buffered glycerol (10% glycerol in PBS, pH 8.59) and slides
were observed with a fluorescence microscope Eclipse 80i (Nikon
Corporation, Tokio, Japan). The samples were interpreted as positive
if green fluorescence was observed on the surface of the germ tubes
and the blastoconidium section of the germinated cells stayed red.
The CAGTA titer was established as the highest serum dilution that
showed green fluorescence on the entire surface of germ tubes. Sam-
ple dilutions 1/160 or further are considered positive for IC.
2.3. Determination of serum antibodies against Als3-N, Hwp1-N and
Met6 by enzyme immune assay (EIA)
The amino terminal fractions of C. albicans Als3 (Als3-N) and
Hwp1 (Hwp1-N) proteins, whose immunogenic characters are
located at the amino terminal end of their respective molecules
(Hoyer et al., 1998; Staab & Sundstrom, 1998), and Met6 were
obtained as recombinant proteins following protocols reported previ-
ously (Laín et al., 2007, Saez-Roson et al., 2014). Microtiter plate wells(Costar, Cambridge, Massachusetts, USA) were loaded with 100 mL of
purified recombinant antigen in 0.05 M sodium bicarbonate buffer
(pH 9.6) (Als3-N or Hwp1-N 0.3 mg/mL, and Met6 1.25 mg/mL) and
left overnight at 4°C; after removing the antigen solution, the wells
were washed with PBS. The internal well surface was blocked with
200 mL of 1% bovine serum albumin in PBS (PBS-BSA) at 37°C for 1
hour, or overnight at 4°C. Microplates can be sealed and stored at
-20°C after removing the blocking solution. Human sera were diluted
1/1000 in PBS and assayed in triplicate (100 mL/well). After 1 h of
incubation at 37°C, the wells were washed 3 times with 200 mL/well
of PBS-Tw (0.05% Tween 20 in PBS). Then, 100 mL of HRP-conjugated
anti−human IgG (Sigma) diluted 1/1000 in PBS-Tw was added to
each well and plates were incubated for 1 h at 37°C. The plates were
washed as described above, and 100 mL of substrate solution (0.05 M
citric acid, 0.1 M di-sodium hydrogen phosphate anhydrous, 0.05% of
30% hydrogen peroxide and 0.05% o-phenylenediamine (Sigma)) was
added to each well. The plates were incubated in the dark for 30
minutes at room temperature. The reaction was stopped by adding
50 mL/well of 0.5 M sulfuric acid, and the absorbance was measured
at 490 nm using a Microplate Autoreader (Bio-Tek Instruments,
Montpelier, Vermont, USA). To normalize the results of different day
assays, we run the same reference control serum in every plate; the
absorbance data were divided by that of the reference serum, and
results were reported as relative absorbance value.
2.4. Serum beta-D-glucan (BDG) determination
Serum BDG was estimated with the Fungitell kit (Associates of
Cape Cod, Inc, E. Falmouth, MA, USA), following the instructions of
the manufacturer. BDG concentration values <60pg/mL were consid-
ered negative, while values ≥80 pg/mL were interpreted as positive.
2.5. Statistics
Mean values of relative absorbance data of the 3 groups of
patients were compared by ANOVA (GraphPad 6), and values of P <
0.05 were considered statistically significant. Receiver-operating-
characteristic (ROC) curve analysis and area under the curve (AUC)
values were used to establish the optimal cut-off value for each anti-
body (Youden index) and to evaluate the overall diagnostic perfor-
mance of the tests. The sensitivity, specificity, positive, and negative
predictive values and accuracy of assays were calculated as described
by Kozinn et al (1978).
3. Results
3.1. Serum CAGTA, antibodies against Als3-N, Hwp1-N and Met6, and
BDG determination
As shown in Fig. 1., regardless of their immune status, patients
with proven IC (G1) achieved the highest CAGTA titers, and the geo-
metric mean showed significant statistical differences with those of
the G2 and G3 control groups (P < 0.05). The antibody response to
Als3-N and Hwp-1-N displayed a similar behavior to CAGTA. It is
noteworthy that, although immunocompromised patients showed
lower antibody levels compared to immunocompetent patients, the
G1 group mean values were always higher than the G2 and G3 con-
trol groups, and differences were statistically significant as well.
Regarding anti−Met6 antibodies, immunocompetent G1
patients showed a slightly higher mean value compared to
patients with other fungal infections (G2), but this difference was
not statistically significant. However, for immunocompromised
patients, the differences in mean values of the 3 groups were sta-
tistically significant.
On the other hand, BDG concentration in the serum of patients
with IFD (G1 and G2) did not show any significant differences
Fig. 1. Distribution of the results of assays for CAGTA and antibodies against Als3-N, Hwp1-N and Met6, and BDG determination in sera of immunocompetent (left column) and
immunocompromised (right column) patients. Group 1: proven invasive candidiasis; Group 2: proven invasive fungal diseases different from candidiasis; Group 3: no evidence of
fungal disease. Mean § SD is represented with red lines; geometric mean is used for CAGTA titers (Color version of the figure is available online.).
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This result was expected because BDG is a cell wall component of
most fungi. Likewise, patients without evidence of fungal infection
showed values below the published cut-off point (80 pg/mL).3.2. ROC curves
The performance of the anti−Als-3, anti−Hwp1-N, and anti−Met6
antibodies tests for the diagnosis of IC was determined through the
Fig. 2. Diagnosis of invasive candidiasis. ROC curves and AUC (area under the curve) values for the determination of specific antibodies against Als3-N, Hwp1-N, and Met6 in immu-
nocompetent and immunocompromised patients. ND line = no discrimination line.
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ues were calculated independently for immunocompetent and
immunocompromised patients.
The AUC value for the determination of anti−Als3-N antibodies in
immunocompetent patients reached the highest value (0.789), corre-
sponding to its discrimination ability, followed by the anti−Hwp1-N
and anti−Met6 antibodies tests (Fig. 2, left panel). In contrast, in
immunocompromised patients, the detection of anti−Met6 antibod-
ies (AUC 0.892) reached the highest discriminating capacity, followed
by anti−Als3-N, and anti−Hwp1-N antibodies tests (Fig. 2, right
panel).
3.3. Diagnostic utility of biomarkers
The calculated parameters for the diagnosis of IC with the differ-
ent biomarker assays are summarized in Table 1. For a 1/160 cut-off,
CAGTA showed modest sensitivity, however specificity and PPV were
high, even 100% in immunocompromised patients. Notably, when
the cut-off was set to 1/80, sensitivity increased from 50% to 61% in
immunocompetent patients, and from 33% to 50% in immunocom-
promised patients, at the cost of a slight decrease in specificity values,Table 1
Overall performance of CAGTA assay, detection of specific antibodies against Als3-N, Hwp1-
nocompetent and immunocompromised patients.





Anti−Als3-N antibodies competent 83
compromised 75
Anti−Hwp1-N antibodies competent 66
compromised 75




a Sens: sensitivity; Spec: specificity; PPV: positive predictive value; NPV: negative predict
b CAGTA-80 and CAGTA-160 refer to the cut-off applied for calculations, 1/80 and 1/160 rbut a higher overall efficacy (accuracy 73% and 88%, respectively).
Specific antibody tests outweighed the low sensitivity of CAGTA
determination, most notably anti−Als3-N antibodies (83%), followed
by anti−Met6 and anti−Hwp1-N antibodies among immunocompe-
tent patients. However, in immunocompromised patients, the detec-
tion of anti−Met6 antibodies reached 92% sensitivity, with a high
NPV (97%); in these patients, anti−Als3-N and anti−Hwp1-N antibod-
ies tests sensitivity (75%), and NPV values (92% and 88%, respectively)
were also remarkable.
BDG detection sensitivity for the diagnosis of IC was 62% to 68%
(Table 1). Of note, in immunocompromised patients, PPV dropped to
33% while NPV reached 87%, with a discreet 65% accuracy.
3.4. Serum biomarkers and species of Candida and related genus
In further analysis, we tried to establish the sensitivity of bio-
markers according to the yeast species causing invasive candidiasis
in Group 1 patients (Table 2). The anti−Met6 antibodies test gave the
best results for the 3 most represented species (C. albicans 84%, Naka-
seomyces glabrata (formerly referred to as Candida glabrata) 88%, and
Candida parapsilosis 100%), followed by anti−Als3-N antibodies (81%,N, and Met6, and BDG determination for the diagnosis of invasive candidiasis in immu-
Speca (%) PPVa (%) NPVa (%) Aa (%)
89 87 65 73
98 86 88 88
95 93 60 70
100 100 85 86
63 74 75 74
74 44 92 74
71 74 62 68
49 29 88 55
49 65 63 65
74 49 97 78
76 78 68 71
65 33 87 65
ive value; A: accuracy.
espectively
Table 2
Positive cases for each biomarker in relation to the yeast species responsible for infection in patients with proven candidiasis (Group 1).
Antibodies anti−
Als3-N Hwp1-N Met6 BDG CAGTA- 80a CAGTA-160a
Yeast Species N N % N % N % N % N % N %
Candida albicans 57 46 81 39 68 48 84 44 77 36 63 35 61
Nakaseomyces glabratab 26 21 81 17 65 23 88 14 54 20 77 14 54
Candida parapsilosis 17 15 88 12 71 17 100 10 59 11 65 6 35
Candida tropicalis 8 6 75 4 50 6 75 4 50 5 62 3 37
Pichia kudriavzeviic 4 3 75 2 50 4 100 2 50 1 25 0 0
Meyerozyma guilliermondiid 3 2 67 1 33 2 67 1 33 0 0 0 0
Clavispora lusitaniaee 2 2 100 2 100 2 100 2 100 1 50 1 50
Kluyveromyces marxianus 1 1 100 0 0 1 100 0 0 1 100 1 100
Candida spp. 16 13 81 11 69 15 94 10 62 5 31 4 25
Total 134
a CAGTA-80 and CAGTA-160 refer to the cut-off applied for calculations, 1/80 and 1/160 respectively.
Yeast species formerly referred to as:
b Candida galbrata, cCandida krusei, dCandida guilliermondii, eCandida lusitaniae and fCandida kefyr.
A.t.S.s.i.c.o. Díez et al. / Diagnostic Microbiology and Infectious Disease 101 (2021) 115509 581%, and 88% respectively). Although Candida tropicalis, and Pichia
kudriavzevii and Meyerozyma guilliermondii (formerly referred to as
Candida krusei and Candida guilliermondii, respectively) were less rep-
resented in this study, these 2 markers also provided the best sensi-
tivity values for these 3 species.
3.5. Combination of test results
To improve the diagnostic indicators of IC obtained using the
assays individually, we tested all possible combinations of the 5
assays. The best results were obtained for combinations of 2 bio-
markers (Table 3); combinations of 3 or more biomarkers improved
sensitivity but resulted in a dramatic decrease of specificity and accu-
racy of the diagnostic strategy (data not shown).
For immunocompetent patients, the combination of anti−Als3-N
antibodies with anti−Met6 antibodies or BDG reached the highest
sensitivity values (95% and 93%, respectively), followed by anti−Met6
antibodies + BDG (92%), with NPV ranging 83% to 85%. However, the
best accuracy numbers corresponded to BDG + CAGTA (79 and 77%)
followed by anti−Als3 antibodies + CAGTA (76%).
In contrast, in immunocompromised patients, the combination of
results of anti−Met6 antibodies and CAGTA tests (92% sensitivity and
74% specificity), independently of the cut-off value applied for CAGTATable 3




Sensa (%) Spec (%)a PPV (%)a NPV (%)a A (%)a Biomarkers
87 52 70 77 72 Als3-N + Hwp1
95 35 65 85 68 Als3-N + Met6
93 50 75 85 74 Als3-N + BDG
89 60 73 82 76 Als3-N + CAGTA-
87 62 74 80 76 Als3-N +CAGTA-
87 38 64 70 65 Hwp1-N + Met6
87 52 70 77 72 Hwp1-N + BDG
77 65 73 70 72 Hwp1-N +CAGTA
75 70 76 69 72 Hwp1-N +CAGTA
92 48 69 83 72 Met6 + BDG
86 51 69 75 71 Met6 + CAGTA-8
83 54 69 72 70 Met6+CAGTA-16
84 72 79 77 79 BDG + CAGTA-80
78 74 79 73 77 BDG+CAGTA-160
a Sens = sensitivity; Spec = specificity; PPV = positive predictive value; NPV = negative pre
b In this table “Als3-N” stands for anti−Als3-N antibodies, “Hwp1-N” for anti−Hwp1-N an
cut-off applied for calculations, 1/80 and 1/160 respectively.rendered the best accuracy indexes (78%). In addition to 74% specific-
ity, this combination reached a 97% NPV.
4. Discussion
Fungal culture and tissue histopathology from usually sterile sites
remain the gold standard tests for IC diagnosis (Donnelly et al., 2020,
Pappas et al., 2016, Pitarch et al., 2018), but culture exhibits low sensi-
tivity (approx. 50%) and it can take 24-48 hours to return a positive
result. A delay of 12 to 24 hours in the introduction of antifungal
treatment may double the attributed mortality (Garey et al., 2006) so
it is crucial to develop new diagnostic tests for the early detection of
this fungal infection.
Candida mannan and anti−mannan detection techniques have
been commercialized to support a diagnosis of IC. Reports for
PlateliaTM Candida Ag Plus (Bio-Rad) indicate sensitivity values of 85%
and specificity of 95% (Sendid et al., 2004), but one of its shortcomings
is that it does not discriminate between colonization and invasion.
BDG is an interesting IFD biomarker detecting infections caused
by Candida, Aspergillus or Pneumocystis. In this study, the sensitivity
of BDG to detect an IFD (70%) was slightly superior to IC (62% to 68%),
as expected for a panfungal marker, but specificity and PPV dropped
dramatically in immunocompromised patients with IC. In theseet6, as well as BDG determination in immunocompetent and immunocompromised
Immunocompromised
patients
Sens (%)a Spec (%)a PPV(%)a NPV (%)a A (%)a
92 45 31 95 55
92 57 37 96 65
87 51 32 94 58
80b 83 73 45 94 75
160b 79 74 45 93 75
96 38 29 97 50
92 33 27 94 45
-80b 92 48 32 96 58
-160b 92 49 33 96 58
96 55 37 98 64
0b 92 74 49 97 78
0b 92 74 49 97 78
b 75 65 37 91 67
b 67 65 34 88 65
dictive value; A = accuracy.
tibodies, and “Met6” for anti−Met6 antibodies; CAGTA-80 and CAGTA-160 refer to the
6 A.t.S.s.i.c.o. Díez et al. / Diagnostic Microbiology and Infectious Disease 101 (2021) 115509patients, our results showed a NPV of 87% for IC, in accordance with
the current ESCMID guidelines recommending serial determination
of BDG in adults at risk, especially to rule out this infection (Cuenca-
Estrella et al., 2012, Cornelius and Nguyen, 2014). The relatively low
specificity of BDG for the diagnosis of IC could be compensated to
some extent by combining results with other tests more specific.
CAGTA detection allows discriminating colonization from inva-
sion (García-Ruiz et al., 1997). Some authors question the usefulness
of antibody detection in immunocompromised patients (Quindos
et al., 2004, Ellepola and Morrison, 2005), and we found that they
have lower CAGTA titers than immunocompetent patients. Neverthe-
less, in both cohorts of patients, CAGTA titers of the proven IC groups
were significantly higher than their respective control groups, includ-
ing patients with other fungal infections. Importantly, CAGTA speci-
ficity was high (89%100%) but, even raising the cut-off to 1/80, as
recommended by Martínez-Jimenez et al. (2015), the sensitivity did
not exceed 61% in immunocompetent patients, and these values
agree with the recently reported data of Pini et al. (2019). Previous
studies of our group claimed higher sensitivity values (García-Ruiz
et al., 1997, Moragues et al., 2004), and Trovato et al. (2020) reported
91.3% sensitivity in long-stay ICU patients, emphasizing the value of
serial monitoring to assess the kinetics of CAGTA for the clinical diag-
nosis of IC. Moreover, the occurrence of CAGTA has been associated
with a lower mortality rate of ICU patients receiving antifungal treat-
ment (Zaragoza et al., 2009).
CAGTA determination offers an interesting support for clinical
practice, but this technique is difficult to automate and requires
trained personnel for microscopy register. Moreover, in IC patients,
authors have identified specific antibodies against certain C. albicans
proteins, which could be useful as serum biomarkers of infection
(Laín et al., 2008); some of these antigens are Met6, Hsp90, Pgk1,
Eno1 (Pitarch et al., 2006, 2007, 2011, 2014, 2016), Als3, or Hwp1
(Laín et al., 2008, Naglik et al., 2006, Ardizzoni et al., 2014). Thus, we
developed enzyme-linked immunosorbent assays, a commonly used
technique in the clinical laboratory, to determine specific antibodies
against recombinant C. albicans Als3-N, Hwp1-N, and Met6 proteins,
and verified their usefulness for the diagnosis of IC.
Similar to CAGTA, mean antibody titers against recombinant pro-
teins Als3-N, Hwp1-N, and Met6 were higher among immunocompe-
tent patients than in immunocompromised patients, but in both
cohorts, IC patients exhibited higher values than their respective con-
trol groups. ROC curves showed that anti−Als3-N antibodies determi-
nation had the highest discriminatory ability for the diagnosis of IC
among immunocompetent patients, followed by anti−Hwp1-N. Con-
versely, in immunocompromised patients, the detection of antibodies
against Met6 recorded the highest AUC value of the 3 proteins tested,
followed by anti−Als3, and in both cases with higher discriminatory
ability than for immunocompetent patients.
Detection of anti−Als3 antibodies in immunocompetent patients
exhibited a sensitivity of 83%, much higher than reported 41.7% (Laín
et al., 2008) or 68.6% (Ardizzoni et al., 2014). In immunocompromised
patients, sensitivity was somewhat lower (75%) but with a high NPV
(92%).
Regarding anti−Hwp1-N antibodies, in contrast to the high values
of sensitivity 88.9%, and NPV 90.2% published by Lain et al. (2007), in
our study the sensitivity reached only 75% in immunocompromised
patients. On the contrary, Ardizzoni et al. (2014) were unable to
assess any diagnostic capability for these antibodies. Although Hwp1
is a protein associated with C. albicans germ tube formation, other
Candida species incapable of forming mycelia may contain proteins
with regions homologous to Hwp1, and therefore induce cross-react-
ing antibodies in patients infected by other species different from C.
albicans (Laín et al., 2007).
In addition to Candida, other fungi express Met6 variants that can
induce cross-reacting antibodies that would reduce the specificity of
the assay. In this regard, in our study, immunocompetent patientswith IC displayed higher anti−Met6 antibody titers than control
patients did, although the difference from the other IFD group was
not statistically significant. As a result, sensitivity was moderate
(77%) with a rather low specificity (49%). Conversely, the detection of
anti−Met6 antibodies in immunocompromised patients showed the
best rates of the 3 tests developed (S 92%, E 74%, NPV 97%, A 78%).
While sensitivity was superior to figures reported previously (60-
65%), the specificity rate did not reach published values (82%83%)
(Pitarch et al., 2007, Clancy et al., 2008); the high specificity reported
by these authors might be due to the absence of patients with other
fungal diseases in their control groups.
From a clinical perspective, anti−Met6 antibodies detection in
immunocompromised patients at risk of IC appears as a promising
test since high sensitivity may guide the diagnosis of IC, and the neg-
ative predictive value of the test could serve as a support to rule out
possible candidemia in this cohort. Consequently, anti−Met6 anti-
bodies results can guide early antifungal treatment or de-escalation
in the absence of specific antibodies. Moreover,
(Pitarch, Nombela and Gil, 2011) found that high IgG antibody levels
against Candida Met6, Hsp90, and Pgk1 was associated with good-
prognosis and protective patterns in patients with IC, so anti−Met6
antibodies detection could be an interesting biomarker to predict
patient clinical-outcome for individualized therapy of IC.
In addition to C. albicans, infections with Nakaseomyces glabrata or
C. parapsilosis triggered measurable antibody responses with high
frequency, especially against Als3-N (81% and 88% respectively) and
Met6 (88 and 100%). Similarly, although less represented in patients
of this study, C. tropicalis, Pichia kudriavzevi or Meyerozyma guillier-
mondii also elicited antibody responses to these 2 proteins. Moragues
et al. (2004) also reported the presence of CAGTA in patients infected
with non−C. albicans species. This phenomenon of cross-reactivity
may be due to short sequence homologies of various proteins of dif-
ferent species of the genus Candida and related ones, as it has been
described for C. albicans Hwp1 and other proteins of C. parapsilosis, C.
tropicalis, N. glabrata or Candida dubliniensis (Laín et al., 2007).
The detection of specific antibodies by EIA exceeded the sensitiv-
ity values of CAGTA in all cases, but at the cost of a significant loss in
specificity; nevertheless, they maintained high NPV levels, especially
in immunocompromised patients. In an attempt to exploit the advan-
tages of the different assays, we analyzed the combinations of differ-
ent test results, and found that combining 3 or more results
increased the sensitivity for IC diagnosis; however, the specificity
dropped dramatically, and therefore we focused on pairwise combi-
nations. For immunocompetent patients, the best combinations of
sensitivity (89-95%) and NPV (83%85%) included anti−Als3 antibod-
ies with CAGTA-80, anti−Met6 antibodies or BDG, as well as anti
−Met6 antibodies with BDG, although the combination of BDG with
CAGTA-80 showed the highest accuracy rate (79%). The combination
of BDG with CAGTA has already been proposed to improve the speci-
ficity of BDG in IC cases (Pini et al., 2019), and Martinez-Jimenez
(2015) recommends raising the CAGTA cut-off point to 1/80. Con-
versely, in immunocompromised patients the best sensitivity
(92%96%) and NPV (96%98%) results were obtained with combina-
tions of anti−Met6 antibodies with anti−Als3 antibodies, BDG or anti
−Hwp1 antibodies. Although the combination of anti−Met6 antibod-
ies with CAGTA showed the highest accuracy rate (78%), the results
did not improve the performance of anti−Met6 antibodies detection
on its own.
5. Conclusions
In view of our results, we can conclude that EIA for detection of
antibodies against C. albicans Als3-N, Hwp1-N, and Met6 proteins are
more sensitive than CAGTA determination, but specificity is generally
lower. However, in the case of immunocompromised patients, the
specificity for anti−Als3-N and anti−Met6 antibodies remains 74%
A.t.S.s.i.c.o. Díez et al. / Diagnostic Microbiology and Infectious Disease 101 (2021) 115509 7while NPV goes up to 92% and 97% respectively. The combined results
of BDG and CAGTA-80 offer the highest diagnostic efficacy in immu-
nocompetent patients; however, for immunocompromised patients,
anti−Met6 antibodies is the best biomarker for IC, both, alone or in
combination with BDG. Laboratory surveillance of at-risk patients
could result in an earlier initiation of antifungal therapy provided
sensitive and specific diagnostic tests, and also cost effective, become
available. De-escalation of established antifungal therapy may also
rely on adequate surveillance of infection with biomarkers. Finally,
evidence of immunologic response of patients against specific Can-
dida antigens can help uncovering potential targets for vaccine design
and immunotherapy against IC.
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